Medication side effects in anxious patients: negative placebo responses?

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Anxiety disorders are common and often treated with benzodiazepines like alprazolam.
• Switching medication formulations can present challenges for patients, potentially impacting treatment outcomes.

Purpose of the Study:

• To evaluate problems encountered by anxious patients when transitioning from immediate-release alprazolam to an extended-release formulation.
• To identify specific adverse events and patient characteristics associated with this medication switch.

Main Methods:

• A study involving 54 patients with anxiety disorders stabilized on alprazolam.
• Patients initially took their usual alprazolam, then switched to the same dosage of extended-release alprazolam for two weeks.
• Weekly clinical evaluations and adverse event monitoring were conducted.

Main Results:

• While overall clinical measures showed modest improvement, the incidence of reported adverse medical events significantly increased from 26% to 60% after switching to extended-release alprazolam.
• The majority of these events were anxiety-like (48%) or sedative (37%).
• Patients experiencing anxiety-like events had higher baseline anxiety and somatization scores, suggesting a potential negative placebo response.

Conclusions:

• The transition to extended-release alprazolam formulation can trigger anxiety-like and sedative adverse events, particularly in patients with higher baseline anxiety and somatization.
• These findings suggest that psychological factors, such as negative placebo responses, may play a significant role in perceived side effects during medication regimen changes.
• Further research is warranted to differentiate pharmacological from psychological effects and elucidate underlying mechanisms.